GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANG Lifesciences India Ltd (BOM:540694) » Definitions » Capex-to-Revenue

ANG Lifesciences India (BOM:540694) Capex-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is ANG Lifesciences India Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

ANG Lifesciences India's Capital Expenditure for the three months ended in Dec. 2024 was ₹0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was ₹247.29 Mil.

Hence, ANG Lifesciences India's Capex-to-Revenue for the three months ended in Dec. 2024 was 0.00.


ANG Lifesciences India Capex-to-Revenue Historical Data

The historical data trend for ANG Lifesciences India's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANG Lifesciences India Capex-to-Revenue Chart

ANG Lifesciences India Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.03 0.12 0.05 0.04

ANG Lifesciences India Quarterly Data
Sep19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ANG Lifesciences India's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, ANG Lifesciences India's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANG Lifesciences India's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANG Lifesciences India's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where ANG Lifesciences India's Capex-to-Revenue falls into.


;
;

ANG Lifesciences India Capex-to-Revenue Calculation

ANG Lifesciences India's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-55.685) / 1460.089
=0.04

ANG Lifesciences India's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 247.291
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ANG Lifesciences India  (BOM:540694) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


ANG Lifesciences India Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of ANG Lifesciences India's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ANG Lifesciences India Business Description

Traded in Other Exchanges
N/A
Address
Ranjit Avenue, B-Block, Darbara Complex, SCO 113, First Floor, District Shopping Complex, Amritsar, PB, IND, 143001
ANG Lifesciences India Ltd is an India-based engaged in the manufacturing of finished pharmaceutical formulations in the form of dry powder for injections. The Group has two reportable segments: Pharmaceuticals which include Manufacturing of pharmaceutical products, and Packaging and printing which include Prinitng and packaging. Key revenue is generated from Pharmaceuticals.

ANG Lifesciences India Headlines

No Headlines